Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) EPS (Weighted Average and Diluted) (2020 - 2025)

Traws Pharma (TRAW) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.71 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 78.81% year-over-year to -$0.71; the TTM value through Dec 2025 reached $0.93, up 102.97%, while the annual FY2025 figure was $0.82, 102.33% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.71 in Q4 2025 for Traws Pharma, down from -$0.34 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.09 in Q1 2025 and bottomed at -$20.52 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.17, with a median of -$0.28 recorded in 2021.
  • Year-over-year, EPS (Weighted Average and Diluted) plummeted 10160.0% in 2024 and then soared 135.3% in 2025.
  • Traws Pharma's EPS (Weighted Average and Diluted) stood at -$0.16 in 2021, then crashed by 62.5% to -$0.26 in 2022, then tumbled by 1815.38% to -$4.98 in 2023, then soared by 32.73% to -$3.35 in 2024, then soared by 78.81% to -$0.71 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.71, -$0.34, and -$0.11 for Q4 2025, Q3 2025, and Q2 2025 respectively.